B. Riley lowered the firm’s price target on Biote (BTMD) to $9 from $10 and keeps a Buy rating on the shares. Biote’s Q4 revenue and AEBITDA ...

Q4 2024 Earnings Call Transcript March 12, 2025 biote Corp. beats earnings expectations. Reported EPS is $0.1, expectations ...

(NASDAQ:BTMD – Get Free Report) had its target price cut by investment analysts at Craig Hallum from $12.00 to $8.00 in a research report issued to clients and investors on Thursday,Benzinga reports.

biote has a 52 week low of $4.03 and a 52 week ... in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance.

2025 Adjusted EBITDA Outlook: $59 million to $64 million. Biote Corp (NASDAQ:BTMD) reported a 9% increase in fourth-quarter revenue, reaching $49.8 million. The company achieved a 247 basis point ...

biote Corp. (Nasdaq: BTMD) (“Biote” or the “Company”), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic ...

And as I think about the value of Biote, we've got fantastic products. So we've got testosterone pellets, we've got the B-glycemic balls, we've got BioteRx. And the way we're starting to form the ...